Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia

NCT06022198 | Completed

• 1 other identifier: MD.21.01.408
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Coronaviruses such as SARS-CoV2, MERS-CoV, and SARS-CoV can cause significant morbidity and mortality in infected persons. Lung is the most common site of infection for these viruses, which may manifest as acute respiratory distress syndrome and mortality. Pulmonary involvement is also responsible for the high viral transmission The aim of this study is to evaluate BAL in post-acute COVID-19 patients for:Cytological and cellular patterns. Microbial analysis for possibility of presence of bacterial, mycobacerial or fungal co-infection.PCR for corona virus

Conditions

Bronchoalveolar Lavage

Keywords

Bronchoalveolar lavage; COVID-19 Pneumonia

Outcome Measures

Primary Outcomes (1)

• evaluate BAL in post-acute COVID-19 patients

  Understanding the pathophysiological mechanisms of COVID-19 and nature of the immunological defense in lungs in response to viral infection by SARS-CoV2 is essential in order to initiate timely and targeted anti-inflammatory, anticoagulative, or even antifibrotic therapy

  Baseline

Study Arms (1)

Recovered From COVID-19 Pneumonia

EXPERIMENTAL

Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia

Procedure: Bronchoalveolar Lavage

Interventions

Bronchoalveolar Lavage PROCEDURE

Bronchoalveolar Lavage

Recovered From COVID-19 Pneumonia

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with persistent pulmonary infiltrate one month after discharge from isolation building at Mansoura university hospitals, previously tested positive for SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab during admission, discharged and discontinued transmission based precautions according to CDC guidance:
• Symptom-Based Strategy for Discontinuing Transmission-Based Precautions (CDC, 2020)
• Patients with mild to moderate illness who are not severely immunocompromised:
• At least 10 days have passed since symptoms first appeared and
• At least 24 hours have passed since last fever without the use of fever-reducing medications and
• Symptoms (e.g., cough, shortness of breath) have improved
• Patients with severe to critical illness or who are severely immunocompromised1:
• At least 10 days and up to 20 days have passed since symptoms first appeared and
• At least 24 hours have passed since last fever without the use of fever-reducing medications and
• Symptoms (e.g., cough, shortness of breath) have improved
• Consider consultation with infection control experts

You may not qualify if:

• Age: patients less than 18 years old.
• Patient refuse to undergo bronchoscopy.
• Patients unfit for bronchoscopy (hemodynamic instability, recent myocardial infarction, severe hypoxia, uncooperative patient, severe bleeding disorder).
• Patients known to have chronic airway pulmonary diseases or interstitial lung diseases

Sponsors & Collaborators

• Mohamed Abd Elmoniem Mohamed: lead
• Marwa Salah Abdelrazek Ghanem: collaborator
• Mohammad Khairy El-Badrawy: collaborator
• Tamer Ali Elhadidy: collaborator
• Dalia Abdellateif Abdelghany: collaborator

Study Sites (1)

Mohamed AbdElmoniem

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Interventions

Bronchoalveolar Lavage

Intervention Hierarchy (Ancestors)

Therapeutic Irrigation; Investigative Techniques

Study Officials

• Marwa Ghanem

  Mansoura university Faculty of medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant lecturer

Model Details: prospective cross sectional study at which COVID-19 patients with persistent pulmonary infiltrate one month after discharge from isolation department at Mansoura university hospitals will be enrolled in the study

Study Record Dates

• First Submitted: August 31, 2023
• First Posted: September 1, 2023
• Study Start: January 1, 2021
• Primary Completion: January 1, 2022
• Study Completion: January 1, 2023
• Last Updated: September 1, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)